Dynamic Changes in Pentraxin-3 and Neprilysin in ST Segment Elevation Myocardial Infarction
Open Access
- 26 January 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (2) , 275
Abstract
Pentraxin-3 (PTX3) and neprilysin have been associated with increased morbidity and mortality in chronic inflammatory disease and heart failure, but these biomarkers have been studied less in patients with ST segment elevation myocardial infarction (STEMI). We investigated the dynamic changes in these biomarkers, as well as the well-known C-reactive protein (CRP), in STEMI patients. PTX3, neprilysin and CRP were measured in samples from 165 STEMI patients, collected at the acute stage, 1–3 days after and 3 months after percutaneous coronary intervention (PCI), and from 40 healthy donors. Patient survival was followed for approximately 8 years after the PCI. As compared with samples from healthy donors, plasma levels of CRP and PTX3 were significantly increased in the acute samples and 1–3 days after PCI, but not at 3 months. CRP levels peaked at 1–3 days, while PTX3 was similarly high in both acute and 1–3 days samples. For neprilysin, no significant differences were observed at the group level. We found no significant differences when comparing patients with patent versus occluded culprit vessels or between patients having a thrombus aspiration or not. However, we found a significant reduction in survival for individuals with PTX3 above the median, both for samples collected at the acute stage and 1–3 days after PCI (p = 0.0001 and p = 0.0008, respectively). For CRP, no significant differences were observed using this approach, but patients above the reference range for healthy donors in the acute samples showed significantly lower survival (p = 0.0476). Conclusions: Survival analysis suggests that PTX3 might be a promising marker to predict mortality in this patient population.Keywords
This publication has 33 references indexed in Scilit:
- Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)European Journal of Heart Failure, 2013
- Associations of Plasma Pentraxin 3 and Monocyte Chemoattractant Protein-1 Concentrations with Cardiovascular Disease in Patients with Chronic Kidney DiseaseRenal Failure, 2011
- Thrombus Aspiration in ST-Elevation myocardial infarction in Scandinavia (TASTE trial). A multicenter, prospective, randomized, controlled clinical registry trial based on the Swedish angiography and angioplasty registry (SCAAR) platform. Study design and rationaleAmerican Heart Journal, 2010
- Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause DeathArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular trapsJournal of Experimental Medicine, 2007
- C-reactive protein in atherosclerosis: A causal factor?Cardiovascular Research, 2006
- Inflammatory markers and cardiovascular health in older adultsCardiovascular Research, 2005
- Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial InfarctionCirculation, 2004
- The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activationJournal of Leukocyte Biology, 2004
- Control of the Acute Phase ResponseJournal of Clinical Investigation, 1978